EUVIMEDEUVIMED entdecken
Crossref

Peptide HLDF-6 Exhibits Neuroprotective Activity in Neurodegenerative Diseases

Yu.A. Zolotarev, A.K. Dadayan

Нейрохимия / Neurochemical Journal · 2025 · 42 (3) · 377

DOI: 10.7868/s3034556125030061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Нейрохимия / Neurochemical Journal, 2025. Verfasst von Yu.A. Zolotarev und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The review is devoted to the analysis of published data on the normalizing and protective activity of the neuroprotective peptide HLDF-6 family. The peptide HLDF-6 (TGENHR) corresponds to fragment 41-46 of the protein differentiation factor HLDF (Human Leukemia Differentiation Factor). The neuroprotective peptide HLDF-6 and its analogue peptide HLDF-6-H (TGEXHR, where X is Hse) exhibit normalizing pharmacological activity, the targets of which are NMDA and metabotropic glutamate, serotonin and opioid systems, interacting with which the neuroprotective, nootropic, anxiolytic, differentiating, antitumor and anti-aging activity of these peptides is realized. In cellular and experimental models of Alzheimer’s disease induced by the introduction of beta-amyloid peptide Ab25–35, as well as a transgenic model of Alzheimer’s disease using B6C3-Tg(APPswe,PSEN1de9)85Dbo (Tg+) mice, the HLDF-6 peptide exhibits neuroprotective and nootropic activity. Chronic use of HLDF-6 peptide at a dose of 250 mg/kg is accompanied by a neuroprotective effect, normalizes steroidogenesis and effectively stimulates the performance of cognitive tasks. In an experimental model of Parkinson’s disease (PD), HLDF-6-H peptide exhibits neuroprotective, anxiolytic and antidepressant activity. Chronic use of HLDF-6-H peptide (intranasally, 3 weeks, 300 mg/kg/day) restores the level of dopamine and its turnover in the striatum, leads to overcoming motor dysfunctions, normalizes the levels of neurotrophin mRNA BDNF and inflammatory mediators TGFβ1, IL-1β and IFNg in parts of the brain, and also normalizes the concentrations of steroids and inflammatory factors in the bloodstream. The peptide HLDF-6-H has therapeutic potential for the creation of a pharmaceutical drug on its basis for the treatment of PD.

Zitieren

APA

Zolotarev, Y., & Dadayan, A. (2025). Peptide HLDF-6 Exhibits Neuroprotective Activity in Neurodegenerative Diseases. Нейрохимия / Neurochemical Journal, 42(3), 377. https://doi.org/10.7868/s3034556125030061

Vancouver

Zolotarev Y, Dadayan A. Peptide HLDF-6 Exhibits Neuroprotective Activity in Neurodegenerative Diseases. Нейрохимия / Neurochemical Journal. 2025;42(3):377. doi:10.7868/s3034556125030061

BibTeX
@article{Zolotarev2025,
  author = {Zolotarev, Yu.A. and Dadayan, A.K.},
  title = {Peptide HLDF-6 Exhibits Neuroprotective Activity in Neurodegenerative Diseases},
  journal = {Нейрохимия / Neurochemical Journal},
  year = {2025},
  volume = {42},
  number = {3},
  pages = {377},
  doi = {10.7868/s3034556125030061}
}
Kostenlos starten →